专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20180346477A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS 审中-公开
公开(公告)号：US20180346477A1
公开(公告)日：2018-12-06
申请号：US16100668
申请日：2018-08-10
申请人： PFIZER INC.
发明人： DAVID LAWRENCE FIRMAN GRAY , LEI ZHANG , JENNIFER ELIZABETH DAVOREN , AMY BETH DOUNAY , IVAN VIKTOROVICH EFREMOV , CHEWAH LEE , SCOT RICHARD MENTE , STEVEN VICTOR O'NEIL , BRUCE NELSEN ROGERS , CHAKRAPANI SUBRAMANYAM
IPC分类号： C07D491/048 , C07D498/04 , C07D471/04
CPC分类号： C07D491/048 , C07D471/04 , C07D498/04
摘要： The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), schizotypal personality disorder, cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, Parkinson's disease, anxiety, and depression.

2. 发明申请

US20180072750A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS 审中-公开
公开(公告)号：US20180072750A1
公开(公告)日：2018-03-15
申请号：US15822493
申请日：2017-11-27
申请人： PFIZER INC.
发明人： DAVID LAWRENCE FIRMAN GRAY , LEI ZHANG , JENNIFER ELIZABETH DAVOREN , AMY BETH DOUNAY , IVAN VIKTOROVICH EFREMOV , CHEWAH LEE , SCOT RICHARD MENTE , STEVEN VICTOR O'NEIL , BRUCE NELSEN ROGERS , CHAKRAPANI SUBRAMANYAM
IPC分类号： C07D491/048 , C07D498/04 , C07D471/04
CPC分类号： C07D491/048 , C07D471/04 , C07D498/04
摘要： The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), schizotypal personality disorder, cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, Parkinson's disease, anxiety, and depression.

3. 发明申请

US20160016907A1 PYRIDINE DERIVATIVES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS 审中-公开
标题翻译：作为MUSCARINIC M1受体的阳离子衍生物
公开(公告)号：US20160016907A1
公开(公告)日：2016-01-21
申请号：US14799621
申请日：2015-07-15
申请人： PFIZER INC.
发明人： MICHAEL AARON BRODNEY , JENNIFER ELIZABETH DAVOREN , MICHELLE RENEE GARNSEY , LEI ZHANG , STEVEN VICTOR O'NEIL
IPC分类号： C07D213/81 , C07D417/14 , C07D401/06 , C07D401/10 , C07D401/14 , C07D405/14 , C07D413/14
CPC分类号： C07D213/81 , C07D401/06 , C07D401/10 , C07D401/14 , C07D405/14 , C07D413/10 , C07D413/14 , C07D417/14
摘要： The present invention provides, in part, compounds of Formula I: N-oxides thereof, and pharmaceutically acceptable salts of the compounds or N-oxides; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M1-mediated (or M1-associated) disorders including, e.g., Alzheimer's disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.
摘要翻译：本发明部分提供式I的化合物：其N-氧化物和化合物或N-氧化物的药学上可接受的盐; 制备过程; 中间体用于制备; 以及含有这些化合物，N-氧化物或盐的组合物及其用于治疗M1介导的（或M1相关）疾病的用途，包括例如阿尔茨海默病，精神分裂症（例如其认知和阴性症状），疼痛，成瘾，和睡眠障碍。

4. 发明公开

US20240182468A1 COMPOUNDS FOR THE ACTIVATION OF AMPK 审中-公开
公开(公告)号：US20240182468A1
公开(公告)日：2024-06-06
申请号：US18484527
申请日：2023-10-11
申请人： PFIZER INC.
发明人： GARY ERIK ASPNES , CHRISTOPHER RYAN BUTLER , MATTHEW FRANK PAUL CALABRESE , KIMBERLY O'KEEFE CAMERON , JOHN MARION CURTO , MICHAEL ERIC GREEN , XINJUN HOU , SHENPING LIU , CHRISTOPHER LEE MCCLENDON , JOHN CHARLES MURRAY , ADVAITA PANCHAGNULA , COLIN RICHARD ROSE , KYLE THOMAS TARANTINO , MEIHUA MIKE TU , RAYOMAND JAL UNWALLA , JOSEPH SCOTT WARMUS , JUN XIAO , QINGYI YANG , LEI ZHANG
IPC分类号： C07D471/04 , A61K31/444 , A61K31/4545 , A61K31/4725 , A61K31/4985 , A61K31/501 , A61K31/519 , A61K31/5377 , A61K45/06 , C07D401/14 , C07D519/00
CPC分类号： C07D471/04 , A61K31/444 , A61K31/4545 , A61K31/4725 , A61K31/4985 , A61K31/501 , A61K31/519 , A61K31/5377 , A61K45/06 , C07D401/14 , C07D519/00
摘要： Described herein are compounds of Formula I,

wherein the variables are defined herein, their use as activators from AMPK, pharmaceutical compositions containing such compounds and their use to treat, for example, heart failure or peripheral vascular disease.

5. 发明申请

US20190002439A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS 审中-公开
公开(公告)号：US20190002439A1
公开(公告)日：2019-01-03
申请号：US16123072
申请日：2018-09-06
申请人： PFIZER INC.
发明人： MICHAEL AARON BRODNEY , JENNIFER ELIZABETH DAVOREN , AMY BETH DOUNAY , IVAN VIKTOROVICH EFREMOV , DAVID LAWRENCE FIRMAN GRAY , MICHAEL ERIC GREEN , JACLYN LOUISE HENDERSON , CHEWAH LEE , SCOT RICHARD MENTE , STEVEN VICTOR O'NEIL , BRUCE NELSEN ROGERS , LEI ZHANG
IPC分类号： C07D401/14 , A61K31/513 , A61K31/501 , A61K31/506 , C07D405/14 , C07D403/12 , C07D401/12 , A61K31/444
CPC分类号： C07D401/14 , A61K31/444 , A61K31/501 , A61K31/506 , A61K31/513 , C07D401/12 , C07D403/12 , C07D405/14
摘要： The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), and Parkinson's disease.

6. 发明申请

US20170057947A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS 审中-公开
标题翻译：异构化合物及其作为多巴胺D1配体使用
公开(公告)号：US20170057947A1
公开(公告)日：2017-03-02
申请号：US15349075
申请日：2016-11-11
申请人： PFIZER INC.
发明人： MICHAEL AARON BRODNEY , JENNIFER ELIZABETH DAVOREN , AMY BETH DOUNAY , IVAN VIKTOROVICH EFREMOV , DAVID LAWRENCE FIRMAN GRAY , MICHAEL ERIC GREEN , JACLYN LOUISE HENDERSON , CHEWAH LEE , SCOT RICHARD MENTE , STEVEN VICTOR O'NEIL , BRUCE NELSEN ROGERS , LEI ZHANG
IPC分类号： C07D401/14 , C07D405/14 , C07D401/12
CPC分类号： C07D401/14 , A61K31/444 , A61K31/501 , A61K31/506 , A61K31/513 , C07D401/12 , C07D403/12 , C07D405/14
摘要： The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, impulsivity, compulsive gambling, overeating, autism spectrum disorder, MCl, age-related cognitive decline, dementia, RLS, Parkinson's disease, Huntington's chorea, anxiety, depression, MDD, TRD, bipolar disorder, chronic apathy, anhedonia, chronic fatigue, post-traumatic stress disorder, seasonal affective disorder, social anxiety disorder, post-partum depression, serotonin syndrome, substance abuse and drug dependence, drug abuse relapse, Tourette's syndrome, tardive dyskinesia, drowsiness, excessive daytime sleepiness, cachexia, inattention, sexual dysfunction, migraine, SLE, hyperglycemia, atherosclerosis, dislipidemia, obesity, diabetes, sepsis, post-ischemic tubular necrosis, renal failure, hyponatremia, resistant edema, narcolepsy, hypertension, congestive heart failure, postoperative ocular hypotonia, sleep disorders, and pain.
摘要翻译：及其药学上可接受的盐; 制备过程; 中间体用于制备; 和含有这些化合物或盐的组合物及其用于治疗D1介导的（或D1相关）疾病的用途，包括例如精神分裂症（例如，其认知和负面症状），认知障碍（例如，与精神分裂症相关的认知障碍，AD ，PD或药物治疗），ADHD，冲动性，强迫性赌博，暴饮暴食，孤独症谱系障碍，MCl，年龄相关认知衰退，痴呆，RLS，帕金森病，亨廷顿舞蹈症，焦虑症，抑郁症，MDD，TRD，双相情感障碍，慢性冷漠，慢性疲劳，创伤后应激障碍，季节性情绪障碍，社会焦虑症，产后抑郁症，血清素综合征，药物滥用和毒品依赖，药物滥用复发，Tourette综合征，迟发性运动障碍，嗜睡，白天过度嗜睡，恶病质，注意力不集中，性功能障碍，偏头痛，SLE，高血糖症，动脉粥样硬化，血脂异常，肥胖，糖尿病，败血症，缺血后小管坏死，肾衰竭，低钠血症，抗性水肿，发作性睡病，高血压，充血性心力衰竭，术后眼睛低血压，睡眠障碍和疼痛。

7. 发明申请

US20150307522A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS 审中-公开
公开(公告)号：US20150307522A1
公开(公告)日：2015-10-29
申请号：US14694039
申请日：2015-04-23
申请人： PFIZER INC.
发明人： DAVID LAWRENCE FIRMAN GRAY , LEI ZHANG , JENNIFER ELIZABETH DAVOREN , AMY BETH DOUNAY , IVAN VIKTOROVICH EFREMOV , SCOT RICHARD MENTE , CHAKRAPANI SUBRAMANYAM
IPC分类号： C07D519/00 , C07D471/04 , C07D491/147 , C07D495/14 , C07D513/04
CPC分类号： C07D519/00 , A61K31/4355 , A61K31/4365 , A61K31/437 , A61K31/497 , A61K31/4985 , A61K31/506 , A61K31/513 , A61K31/519 , C07D471/04 , C07D491/048 , C07D491/147 , C07D495/04 , C07D495/14 , C07D513/04
摘要： The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), schizotypal personality disorder, cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, Parkinson's disease, anxiety, and depression.

8. 发明申请

US20140336176A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS 审中-公开
标题翻译：异构化合物及其作为多巴胺D1配体使用
公开(公告)号：US20140336176A1
公开(公告)日：2014-11-13
申请号：US14339123
申请日：2014-07-23
申请人： PFIZER INC.
发明人： JENNIFER ELIZABETH DAVOREN , AMY BETH DOUNAY , IVAN VIKTOROVICH EFREMOV , DAVID LAWRENCE FIRMAN GRAY , SCOT RICHARD MENTE , STEVEN VICTOR O'NEIL , BRUCE NELSEN ROGERS , CHAKRAPANI SUBRAMANYAM , LEI ZHANG
IPC分类号： C07D471/04
CPC分类号： C07D471/04 , A61K31/437 , C07D401/04 , C07D401/14 , C07D519/00
摘要： The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof and N-oxides of the foregoing; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, salts or N-oxides, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, impulsivity, compulsive gambling, overeating, autism spectrum disorder, MCI, age-related cognitive decline, dementia, RLS, Parkinson's disease, Huntington's chorea, anxiety, depression, MDD, TRD, and bipolar disorder.
摘要翻译：本发明部分提供式I化合物及其药学上可接受的盐和上述的N-氧化物; 制备过程; 中间体用于制备; 和含有这些化合物，盐或N-氧化物的组合物及其用于治疗D1介导的（或D1相关）疾病的用途，包括例如精神分裂症（例如，其认知和负面症状），认知障碍（例如，认知障碍相关精神分裂症，AD，PD或药物治疗），ADHD，冲动，强迫性赌博，暴饮暴食，孤独症谱系障碍，MCI，年龄相关认知衰退，痴呆，RLS，帕金森病，亨廷顿舞蹈病，焦虑，抑郁，MDD，TRD 和双相情感障碍。

9. 发明申请

US20140128374A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS 有权
公开(公告)号：US20140128374A1
公开(公告)日：2014-05-08
申请号：US14072563
申请日：2013-11-05
申请人： PFIZER INC.
发明人： JENNIFER ELIZABETH DAVOREN , AMY BETH DOUNAY , IVAN VIKTOROVICH EFREMOV , DAVID LAWRENCE FIRMAN GRAY , SCOT RICHARD MENTE , STEVEN VICTOR O'NEIL , BRUCE NELSEN ROGERS , CHAKRAPANI SUBRAMANYAM , LEI ZHANG
IPC分类号： C07D471/04
CPC分类号： C07D471/04 , A61K31/437 , C07D401/04 , C07D401/14 , C07D519/00
摘要： The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof and N-oxides of the foregoing; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, salts or N-oxides, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, impulsivity, compulsive gambling, overeating, autism spectrum disorder, MCI, age-related cognitive decline, dementia, RLS, Parkinson's disease, Huntington's chorea, anxiety, depression, MDD, TRD, and bipolar disorder.

10. 发明申请

US20170044174A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS 审中-公开
标题翻译：杂环化合物及其作为多巴胺D1配体使用
公开(公告)号：US20170044174A1
公开(公告)日：2017-02-16
申请号：US15305384
申请日：2015-04-14
申请人： PFIZER INC.
发明人： DAVID LAWRENCE FIRMAN GRAY , LEI ZHANG , MICHAEL AARON BRODNEY , JENNIFER ELIZABETH DAVOREN , IVAN VIKTOROVICH EFREMOV , MICHAEL ERIC GREEN , STEVEN VICTOR O'NEIL , BRUCE NELSEN ROGERS
IPC分类号： C07D491/048 , C07D403/12 , C07D491/052 , C07D471/04 , C07D487/04
CPC分类号： C07D491/048 , C07D403/12 , C07D471/04 , C07D487/04 , C07D491/052
摘要： The present invention provides, in part, compounds of Formula (I): and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), schizotypal personality disorder, cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, Parkinson's disease, anxiety, and depression.
摘要翻译：本发明部分提供式（I）的化合物及其药学上可接受的盐; 制备过程; 中间体用于制备; 以及含有这些化合物或盐的组合物及其用于治疗D1介导的（或D1相关）疾病的用途，包括例如精神分裂症（例如其认知和阴性症状），分裂型人格障碍，认知障碍（例如认知障碍相关精神分裂症，AD，PD或药物治疗），ADHD，帕金森病，焦虑和抑郁。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式